Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Inclusion criteria

• Body mass index 18.0 to 30.0 kg/m^2, inclusive
• Body weight ≤102 kg
• Willing to consume a high-fat breakfast, including pork
• Adheres to the contraception requirements of the protocol
• Additional criteria apply.

Exclusion criteria

• Received any investigational drug or device in a clinical research study within 90 days
• Evidence of current severe acute respiratory syndrome (SARS-CoV-2) infection
• History of any drug or alcohol abuse in the past 2 years; a confirmed positive drugs of abuse test result
• Regular alcohol consumption; a confirmed positive alcohol breath test at screening
• Current smoker; a confirmed positive breath carbon monoxide reading; current user of e-cigarettes and nicotine replacement products in the last 6 months
• Female of childbearing potential, pregnant, or breastfeeding
• Male participant with pregnant or lactating partners
• Clinically significant abnormal clinical chemistry, hematology or urinalysis result
• Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV)
• Active renal and/or hepatic disease
• History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal (GI), neurological or psychiatric disorder
• Any form of cancer in the 5 years (exceptions apply)
• History of adrenal insufficiency
• Have a condition that could be aggravated by glucocorticoid antagonism
• Donation or loss of greater than 400 mL of blood or plasma within the previous 3 months
• Currently using glucocorticoids or have a history of systemic glucocorticoid use in the last 12 months or 3 months for inhaled products
• Additional criteria apply.